Palvella Therapeutics apponts Matthew Korenberg as CFO

Written by Emily J. Thompson, Senior Investment Analyst

PIRS%

LGND-1.59%

Updated: Oct 17 2024

0mins

New CFO Appointment: Palvella Therapeutics has appointed Matthew Korenberg as CFO, who brings over 27 years of experience in biotech and healthcare investment banking, previously serving as President and COO at Ligand Pharmaceuticals.
Merger Announcement: In July 2024, Palvella and Pieris Pharmaceuticals announced a definitive merger agreement to combine the companies in an all-stock transaction.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Palvella Therapeutics apponts Matthew Korenberg as CFO

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Bitcoin, Ethereum, and Solana Poised for Comeback in 2026

Nvidia Projects Data Center Market to Reach $4 Trillion by 2030

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch